San Francisco, 1 February 2019: The Report Cervical Cancer Treatment Market Size, Share & Trends Analysis Report By Type
(SCC, Adenocarcinoma), By Product (Prevention, Treatment), By Distribution
Channel (Online, Hospital Pharmacies), And Segment Forecasts, 2018 - 2025
The global cervical cancer treatment market size is expected to reach USD 10.6 billion by 2025,
according to a new report by Grand View Research, Inc. The market is projected
to record a CAGR of 5.0% over the forecast period. Increased treatment
penetration and rising disease incidence are projected to drive the market
growth over the next few years. Although, sexually transmitted HPV is a major
cause, the disease can also be triggered by other factors, such as oral
contraceptives, multiple sexual partners, smoking, and HIV infection. There are
more than 100 strains of HPV, 13 of which are high-risk or cancerous. Squamous
cell carcinoma is the most common type and it accounts for nearly 85% of the
overall cases.
The differentiation between squamous cell
carcinoma and adenocarcinoma is based on the histology, as observed under the
microscope. Cervical adenosquamous carcinoma is rare, involving a mixture of
squamous and glandular tissues. Products for cervical cancer can be broadly
classified into prevention and treatment. Preventive options involve vaccines
against HPV. Currently, there are two commercial vaccines – Gardasil and
Cervarix. Treatment options include biologics, such as Avastin and generics
like topotecan, cisplatin, bleomycin, fluorouracil, paclitaxel, carboplatin,
and doxorubicin. The development of targeted therapeutics with improved
efficacy and reduced cost remains a key unmet need of this market.
Nevertheless, expanding focus on the research and development in oncology,
including cervical cancer, indicate a promising future for this market.
Access Research Report of Cervical Cancer Treatment Market @ www.grandviewresearch.com/industry-analysis/cervical-cancer-treatment-market
Further key findings from the study suggest:
· HPV affects nearly 95% of all cervical
cancer cases. HPV strains 16 and 18 account for nearly 70% of all cases
reported
· Nearly three-fourth of all cases occur in
developing and underdeveloped regions (mostly, in Asia and Africa), where
healthcare facilities are limited and awareness about diagnosis and treatment
is low
· North America was the dominant region in
the global cervical cancer treatment market and is expected to continue its
dominance over the estimated period
· This growth is attributed to growing target
population patient, increasing market penetration of drugs, and easy
accessibility to advanced treatments
· Some of the key companies in the market
include F. Hoffmann-LA Roche AG; Merck & Co., Inc.; GlaxoSmithKline PLC;
Allergan PLC; Pfizer, Inc.; Biocon Ltd.; Bristol-Myers Squibb Company;
AstraZeneca PLC; and Eli Lilly & Co.
· Merck & Co. led the competitive space
and is likely to continue to be the largest shareholder due to strong
commercial performances of Gardasil and Keytruda
Browse more reports of this category by Grand View
Research at: www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the
global cervical cancer treatment market on the basis of type, product,
distribution channel, and region:
Cervical Cancer Treatment Type Outlook
(Revenue, USD Million, 2014 - 2025)
·
Squamous Cell Carcinoma (SCC)
·
Adenocarcinoma
·
Adenosquamous Carcinoma
Cervical Cancer Treatment Product
Outlook (Revenue, USD Million, 2014 - 2025)
·
Prevention
·
Treatment
Cervical Cancer Treatment Distribution Channel
Outlook (Revenue, USD Million, 2014 - 2025)
·
Hospital Pharmacies
·
Retail Pharmacies
·
Online Pharmacies
Cervical Cancer Treatment Regional
Outlook (Revenue, USD Million, 2014 - 2025)
·
North America
·
Europe
·
Asia Pacific
·
Latin America
·
Middle East & Africa
Access Press Release of
Cervical Cancer Treatment Market@ www.grandviewresearch.com/press-release/global-cervical-cancer-treatment-market
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
No comments:
Post a Comment